Imagine a future where we can safely prevent a life-threatening condition for mothers and babies, a condition that affects thousands of pregnancies each year. It's a bold statement, but one that researchers are now backing up with evidence.
Pre-eclampsia, a silent threat to many pregnancies, can now be tackled with a new strategy.
By implementing a 36-week screening process and personalizing birth timing, researchers have found a way to reduce the occurrence of pre-eclampsia at term. This innovative approach has the potential to revolutionize late-pregnancy care for women at the highest risk.
But here's where it gets controversial...
While pre-eclampsia is a well-known hypertensive disorder, there has been a lack of proven interventions to tackle it effectively. However, a recent study published in The Lancet offers a glimmer of hope.
The study, titled "Scheduled Birth at Term for the Prevention of Pre-eclampsia (PREVENT-PE): An Open-Label Randomized Controlled Trial," aimed to examine whether screening at 36 weeks, followed by a planned early-term delivery, could reduce pre-eclampsia rates.
Pre-eclampsia is a major concern, causing severe illness and even death for both mothers and babies. On average, it complicates 3% of pregnancies, with approximately 75% of cases occurring at term. These late-term cases account for a significant proportion of maternal and perinatal deaths or severe illnesses.
The Fetal Medicine Foundation (FMF) has developed a competing-risks model that can predict pre-eclampsia. Applied at 11-13 weeks, it identifies around 10% of women as high-risk, and it's accurate in predicting 75% of preterm pre-eclampsia cases.
Preventive measures, such as aspirin, can reduce preterm pre-eclampsia rates, but they fall short when it comes to term pre-eclampsia. This is where the FMF model steps in again, this time at 35-36 weeks, to predict late preterm and term pre-eclampsia, identifying around 70% of at-risk women.
The current study builds on previous research suggesting that elective induction at term could reduce pre-eclampsia rates. Both a Cochrane review and a randomized trial support this approach, especially when combined with 36-week screening and planned early-term birth for at-risk women.
The PREVENT-PE trial, conducted at two UK maternity hospitals, involved over 8,000 women. These women were randomly assigned to either the intervention or control group. At 36 weeks, their pre-eclampsia risk was assessed using the FMF model, which considers various maternal factors, medical history, serum biomarkers, and mean arterial pressure.
Women identified as high-risk (1 in 50 or higher) in the intervention group were offered a risk-stratified planned birth between 37 and 40 weeks. The majority (around 78%) were classified as low-risk and received usual care. Women in the control group also received standard care, regardless of their risk status.
The results were promising. Among the intervention group, pre-eclampsia occurred in only 4% of women, compared to 5.6% in the control group. This translates to a 30% relative reduction in pre-eclampsia risk. Importantly, there were no increases in serious adverse events, postpartum pre-eclampsia, emergency C-sections, or neonatal intensive care admissions.
What's more, the high participation rate (around 75%) suggests that risk-based timed birth at term is an acceptable option for many women.
This strategy, guided by a personalized risk assessment at 36 weeks, offers a new way to prevent pre-eclampsia at term without increasing maternal or neonatal complications. It's a significant step forward and the first randomized trial to report such findings using a personalized, risk-stratified approach.
And this is the part most people miss...
While the findings are promising, further evaluation of the costs and benefits, as well as the experiences of women and clinical staff, is needed. Only then can we fully understand the implications and potential impact of this strategy.
So, what do you think? Is this a game-changer for late-pregnancy care? Could this strategy be the key to reducing pre-eclampsia-related complications? We'd love to hear your thoughts in the comments below!
